Literature DB >> 12438441

Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies.

Manuela Neumann1, Philipp J Kahle, Benoit I Giasson, Laurence Ozmen, Edilio Borroni, Will Spooren, Veronika Müller, Sabine Odoy, Hideo Fujiwara, Masato Hasegawa, Takeshi Iwatsubo, John Q Trojanowski, Hans A Kretzschmar, Christian Haass.   

Abstract

The pathological modifications of alpha-synuclein (alphaS) in Parkinson disease and related diseases are poorly understood. We have detected misfolded alphaS in situ based on the proteinase K resistance (PK resistance) of alphaS fibrils, and using specific antibodies against S129-phosphorylated alphaS as well as oxidized alphaS. Unexpectedly massive neuritic pathology was found in affected human brain regions, in addition to classical alphaS pathology. PK resistance and abnormal phosphorylation of alphaS developed with increasing age in (Thy1)-h[A30P] alphaS transgenic mice, concomitant with formation of argyrophilic, thioflavin S-positive, and electron-dense inclusions that were occasionally ubiquitinated. alphaS pathology in the transgenic mice was predominantly in the brainstem and spinal cord. Astrogliosis was found in these heavily affected tissues. Homozygous mice showed the same pathology approximately one year earlier. The transgenic mice showed a progressive deterioration of locomotor function. Thus, misfolding and hyperphosphorylation of alphaS may cause dysfunction of affected brain regions.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12438441      PMCID: PMC151810          DOI: 10.1172/JCI15777

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  52 in total

1.  Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform.

Authors:  T Ishihara; M Hong; B Zhang; Y Nakagawa; M K Lee; J Q Trojanowski; V M Lee
Journal:  Neuron       Date:  1999-11       Impact factor: 17.173

2.  Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system.

Authors:  A Abeliovich; Y Schmitz; I Fariñas; D Choi-Lundberg; W H Ho; P E Castillo; N Shinsky; J M Verdugo; M Armanini; A Ryan; M Hynes; H Phillips; D Sulzer; A Rosenthal
Journal:  Neuron       Date:  2000-01       Impact factor: 17.173

3.  Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid.

Authors:  K A Conway; J D Harper; P T Lansbury
Journal:  Biochemistry       Date:  2000-03-14       Impact factor: 3.162

4.  Alpha-synuclein in Lewy bodies.

Authors:  M G Spillantini; M L Schmidt; V M Lee; J Q Trojanowski; R Jakes; M Goedert
Journal:  Nature       Date:  1997-08-28       Impact factor: 49.962

5.  Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons.

Authors:  D D Murphy; S M Rueter; J Q Trojanowski; V M Lee
Journal:  J Neurosci       Date:  2000-05-01       Impact factor: 6.167

6.  The paraffin-embedded tissue blot detects PrP(Sc) early in the incubation time in prion diseases.

Authors:  W J Schulz-Schaeffer; S Tschöke; N Kranefuss; W Dröse; D Hause-Reitner; A Giese; M H Groschup; H A Kretzschmar
Journal:  Am J Pathol       Date:  2000-01       Impact factor: 4.307

7.  Dityrosine cross-linking promotes formation of stable alpha -synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies.

Authors:  J M Souza; B I Giasson; Q Chen; V M Lee; H Ischiropoulos
Journal:  J Biol Chem       Date:  2000-06-16       Impact factor: 5.157

8.  A Drosophila model of Parkinson's disease.

Authors:  M B Feany; W W Bender
Journal:  Nature       Date:  2000-03-23       Impact factor: 49.962

9.  Constitutive phosphorylation of the Parkinson's disease associated alpha-synuclein.

Authors:  M Okochi; J Walter; A Koyama; S Nakajo; M Baba; T Iwatsubo; L Meijer; P J Kahle; C Haass
Journal:  J Biol Chem       Date:  2000-01-07       Impact factor: 5.157

10.  Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders.

Authors:  E Masliah; E Rockenstein; I Veinbergs; M Mallory; M Hashimoto; A Takeda; Y Sagara; A Sisk; L Mucke
Journal:  Science       Date:  2000-02-18       Impact factor: 47.728

View more
  144 in total

1.  Mutual exacerbation of peroxisome proliferator-activated receptor γ coactivator 1α deregulation and α-synuclein oligomerization.

Authors:  Judith Eschbach; Björn von Einem; Kathrin Müller; Hanna Bayer; Annika Scheffold; Bradley E Morrison; K Lenhard Rudolph; Dietmar R Thal; Anke Witting; Patrick Weydt; Markus Otto; Michael Fauler; Birgit Liss; Pamela J McLean; Albert R La Spada; Albert C Ludolph; Jochen H Weishaupt; Karin M Danzer
Journal:  Ann Neurol       Date:  2014-12-19       Impact factor: 10.422

2.  Attack on amyloid.

Authors:  Philipp J Kahle; Bart De Strooper
Journal:  EMBO Rep       Date:  2003-07-25       Impact factor: 8.807

Review 3.  Paraffin-embedded tissue (PET) blot method: application to Alzheimer disease.

Authors:  Calvin F Moh; Sandra L Siedlak; Massimo Tabaton; George Perry; Rudy J Castellani; Mark A Smith
Journal:  J Neurosci Methods       Date:  2010-05-16       Impact factor: 2.390

Review 4.  Genetically engineered mouse models of Parkinson's disease.

Authors:  Donna M Crabtree; Jianhua Zhang
Journal:  Brain Res Bull       Date:  2011-08-03       Impact factor: 4.077

5.  Alpha-synuclein aggregation induced by brief ischemia negatively impacts neuronal survival in vivo: a study in [A30P]alpha-synuclein transgenic mouse.

Authors:  Isin Unal-Cevik; Yasemin Gursoy-Ozdemir; Muge Yemisci; Sevda Lule; Gunfer Gurer; Alp Can; Veronica Müller; Philip J Kahle; Turgay Dalkara
Journal:  J Cereb Blood Flow Metab       Date:  2010-09-29       Impact factor: 6.200

6.  Oxidative stress in transgenic mice with oligodendroglial alpha-synuclein overexpression replicates the characteristic neuropathology of multiple system atrophy.

Authors:  Nadia Stefanova; Markus Reindl; Manuela Neumann; Christian Haass; Werner Poewe; Philipp J Kahle; Gregor K Wenning
Journal:  Am J Pathol       Date:  2005-03       Impact factor: 4.307

7.  Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease.

Authors:  Christophe Lo Bianco; Bernard L Schneider; Matthias Bauer; Ali Sajadi; Alexis Brice; Takeshi Iwatsubo; Patrick Aebischer
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-02       Impact factor: 11.205

Review 8.  Molecular mechanisms of alpha-synuclein neurodegeneration.

Authors:  Elisa A Waxman; Benoit I Giasson
Journal:  Biochim Biophys Acta       Date:  2008-10-09

Review 9.  α-Synuclein oligomers and clinical implications for Parkinson disease.

Authors:  Lorraine V Kalia; Suneil K Kalia; Pamela J McLean; Andres M Lozano; Anthony E Lang
Journal:  Ann Neurol       Date:  2012-12-07       Impact factor: 10.422

10.  Specificity and regulation of casein kinase-mediated phosphorylation of alpha-synuclein.

Authors:  Elisa A Waxman; Benoit I Giasson
Journal:  J Neuropathol Exp Neurol       Date:  2008-05       Impact factor: 3.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.